BofA lowered the firm’s price target on Amdocs (DOX) to $97 from $100 and keeps a Buy rating on the shares. Growth remains constrained and the FY26 guidance for revenue growth and EPS, at 3.7% and $7.44, were below the Street’s forecasts of 4.1% and $7.66, respectively, notes the analyst, who expects the year to start slow and ramp in the second half.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DOX:
- Amdocs: Buy Rating Affirmed Amid Strong Backlog, Cloud Growth, and AI Opportunities
- Amdocs Reports Fiscal 2025 Earnings and Strategic Outlook
- Amdocs expands managed services agreement with Globe
- Amdocs signs pact with Vivo to modernize operations support systems
- Amdocs enters multi-year strategic agreement with Telia Finland